News

Ipsen’s Kayfanda (odevixibat) has been approved, under exceptional circumstances, in the European Union (EU) to treat cholestatic pruritus in people with Alagille syndrome,…

October is National Liver Awareness Month, and the American Liver Foundation (ALF) is promoting a series of activities and events to call attention to…

Two infusions of the investigational therapy CNP-104 safely reduced liver scarring (fibrosis) and led to beneficial changes in disease-related immune cell populations among adults with…

Biliary diversion surgery — which can be used in patients with bile duct problems — successfully reduced markers of liver damage, lessened itching, and improved…

Signs of improved liver health are evident in biomarker and liver scarring assessments of people with metabolic-associated steatohepatitis or MASH — a severe form of…

A non-invasive liver function score called the aspartate aminotransferase to platelet ratio index (APRI) may help accurately predict whether adult biliary atresia (BA) patients…

A researcher at the Virginia-Maryland College of Veterinary Medicine received a $2 million award from the National Institutes of Health (NIH) to continue research into…

Iqirvo (elafibranor) has been conditionally approved in the European Union to treat adults with primary biliary cholangitis (PBC), either in combination with the…

Abnormal levels of certain fatty molecules, or lipids, in the blood appear to increase the risk of intrahepatic cholestasis of pregnancy (ICP) and its…

Once daily treatment with oral ALG-055009 safely lowered levels of liver fat in people with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty…